Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Margo Jimenez

Podiatrist Atlanta, GA Doctor of Podiatric Medicine

NPI 1083670673 CMS profile 230547

2295 Parklake Dr Ne Ste 150, Atlanta, GA 30345

Open in the dashboard

General payments

$18,700

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margo Jimenez of Atlanta, GA is reported in the CMS Open Payments database as having received $18,700 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $200 11
2024 General $17,142 17
2023 General $347 13
2022 General $803 23
2021 General $166 5
2019 General $43 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margo Jimenez
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Margo Jimenez were reported at $200. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Margo Jimenez Podiatrist median Middle half National median
2019 $43 $196 $72–$601 $163
2020 $0 $118 $38–$335 $114
2021 $166 $169 $57–$573 $132
2022 $803 $220 $74–$782 $149
2023 $347 $208 $71–$635 $160
2024 $17,142 $237 $87–$681 $164
2025 $200 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $16,823 4 payments
  2. Organogenesis Inc. $627 26 payments
  3. Nevro Corp. $412 7 payments
  4. Medtronic, Inc. $151 2 payments
  5. Treace Medical Concepts, Inc. $115 4 payments
  6. Horizon Therapeutics plc $64 4 payments
  7. Xtant Medical Inc $58 1 payment
  8. OSSIO Inc. $53 1 payment
  9. Paratek Pharmaceuticals, Inc. $52 3 payments
  10. Bioventus LLC $50 2 payments
  11. Other $295 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $16,800 3 payments
  2. Food and Beverage $1,845 67 payments
  3. Travel and Lodging $55 2 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $16,855 6 payments
  2. Omnia $382 6 payments
  3. Puraply $369 10 payments
  4. ClosureFast $133 1 payment
  5. LAPIPLASTY SYSTEM $95 3 payments
  6. NUZYRA $52 3 payments
  7. KRYSTEXXA $39 3 payments
  8. GRAFIX PL $33 2 payments
  9. STRAVIX $33 2 payments
  10. Senza $30 1 payment
  11. Other $576 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

207

Median for Podiatry: 160

Drug cost

$1,335

Median for Podiatry: $2,368

Branded share of claims

11.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amitriptyline Hcl Generic 90 $414
Cephalexin Generic 32 $265
Gabapentin Generic 26 $217
Silver Sulfadiazine Generic 20 $184
Methylprednisolone Generic 15 $118
Ssd Silver Sulfadiazine Brand 12 $70
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$187,232

Of which drugs: $112,054

Medicare patients

221

Average age 74

Services billed

1,381

120 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 37%
Ischemic heart disease 29%
Chronic kidney disease 26%
Depression 21%
Heart failure 16%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Cygnus dual, per square centimeter Q4282 Office 11 150 $89,293

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record